Abstract 142P
Background
Pancreatic cancer (PC) remains a major health concern due to its dismal prognosis and high mortality rates. Hypoxia-inducible factor 1-alpha (HIF-1α) is implicated in promoting tumor growth, angiogenesis, and metabolic changes under hypoxic conditions. However, an all-inclusive understanding of HIF-1α's precise role and clinical impact on PC is yet to be ascertained. This study aims to study the influence of HIF-1α on PC. Specifically, the goal is to assess differences in overall survival (OS) and OS in the context of metastasis between PC patients with high and low expression of HIF-1α.
Methods
We comprehensively searched PubMed, Embase, and the Cochrane Library databases for relevant research articles published until December 2022. Studies eligible for inclusion compared clinical outcomes in PC patients expressing high and low levels of HIF-1α. Primary outcomes of interest were OS and OS in patients with metastasis, computed using the hazard ratio (HR). The R software (version 4.0.3) with metafor and meta packages was used for all statistical analyses, utilizing random-effects models.
Results
Our meta-analysis encompassed 16 studies, representing a cohort of 1,080 PC patients, including 566 with high HIF-1α expression and 514 with low HIF-1α expression. The pooled HR for OS was 1.86 (95% CI: 1.64-2.12, P<0.01, I2=0%), indicating significantly lower survival rates among patients expressing high HIF-1α. More crucially, the pooled HR for OS in patients with metastasis was 2.09 (95% CI: 1.67-2.64, P<0.01, I2=0%), suggesting an even poorer survival outcome in metastatic PC patients with high HIF-1α expression.
Conclusions
Our findings highlight the considerable prognostic role of HIF-1α in PC, particularly elucidating its fundamental role in disease progression and prognosis, especially in the context of metastasis. These insights could stimulate the development of innovative therapeutic strategies that target HIF-1α, with potential implications for enhancing survival rates in PC patients. Further studies should validate these findings in larger, prospective cohorts and further investigate the specific mechanisms through which HIF-1α exacerbates PC progression, particularly in metastatic cases.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
93P - A new platform for fast-track molecular stratification of endometrial carcinomas enabling timely treatment decisions in precision oncology
Presenter: Susanne Walz
Session: Cocktail & Poster Display session
Resources:
Abstract
94P - Harnessing circulating tumor DNA in bronchoalveolar lavage fluid for precise molecular diagnosis of NSCLC
Presenter: Frank Borm
Session: Cocktail & Poster Display session
Resources:
Abstract
95P - Automatic data processing to identify EGFR mutations in pathology reports of patients with non-small cell lung cancer (NSCLC)
Presenter: Betzabel Cajiao Garcia
Session: Cocktail & Poster Display session
Resources:
Abstract
96P - Analysis of concordance between microsatellite instability by next generation sequencing (NGS-MSI) and mismatch repair deficiency by immunohistochemistry (IHC-MMR) in endometrial cancer (EC) patients
Presenter: Simona Duranti
Session: Cocktail & Poster Display session
Resources:
Abstract
97P - Prospects of liquid biopsy in determining prognosis in children with HGG and DIPG
Presenter: Olga Regentova
Session: Cocktail & Poster Display session
Resources:
Abstract
98P - Liquid biopsy in NSCLC: A promising tool to predict immunotherapy response
Presenter: Ana Fernández
Session: Cocktail & Poster Display session
Resources:
Abstract
99P - Comprehensive genomic sequencing as an ancillary diagnostic tool for pathologists
Presenter: Dan Miller
Session: Cocktail & Poster Display session
Resources:
Abstract
100P - Standard serum biomarkers to help predict a cancer diagnosis in patients with non-specific symptoms: Data from Guy´s rapid diagnostic clinic
Presenter: Maria Monroy Iglesias
Session: Cocktail & Poster Display session
Resources:
Abstract
101P - Patient-derived organoids to optimize CDK4/6 inhibitor-based treatment selection in early breast cancer
Presenter: Carla Alves
Session: Cocktail & Poster Display session
Resources:
Abstract
102P - MicroRNAs in urine and saliva as non-invasive biomarkers of minimal residual disease in pediatric acute lymphoblastic leukemia
Presenter: Alejandra Pando-Caciano
Session: Cocktail & Poster Display session
Resources:
Abstract